4.4 Review

Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ijpddr.2012.01.003

Keywords

Leishmania; Leishmaniasis; Drug discovery; High throughput screening

Ask authors/readers for more resources

Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and development. Most antileishmanial drugs are highly toxic, present resistance issues or require hospitalization, being therefore not adequate to the field. Recently improvements have been achieved by combination therapy, reducing the time and cost of treatment. Nonetheless, new drugs are still urgently needed. In this review, we describe the current visceral leishmaniasis (VL) treatments and their limitations. We also discuss the new strategies in the drug discovery field including the development and implementation of high-throughput screening (HTS) assays and the joint efforts of international teams to deliver clinical candidates. (C) 2012 Australian Society for Parasitology Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Using a PCR-Based Method To Analyze and Model Large, Heterogeneous Populations of DNA

Helena Andrade, Alvin K. Thomas, Weilin Lin, Francesco V. Reddavide, Yixin Zhang

CHEMBIOCHEM (2020)

Article Biochemistry & Molecular Biology

Palstimolide A: A Complex Polyhydroxy Macrolide with Antiparasitic Activity

Lena Keller, Jair L. Siqueira-Neto, Julia M. Souza, Korina Eribez, Gregory M. LaMonte, Jennifer E. Smith, William H. Gerwick

MOLECULES (2020)

Article Infectious Diseases

Molecular dissection of Chagas induced cardiomyopathy reveals central disease associated and druggable signaling pathways

Jacob M. Wozniak, Tatiana Araujo Silva, Diane Thomas, Jair L. Siqueira-Neto, James H. McKerrow, David J. Gonzalez, Claudia M. Calvet

PLOS NEGLECTED TROPICAL DISEASES (2020)

Article Microbiology

High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi

Jean A. Bernatchez, Emily Chen, Mitchell Hull, Case W. McNamara, James H. McKerrow, Jair L. Siqueira-Neto

MICROORGANISMS (2020)

Article Oncology

The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies

Briana C. Prager, Harish N. Vasudevan, Deobrat Dixit, Jean A. Bernatchez, Qiulian Wu, Lisa C. Wallace, Shruti Bhargava, Derrick Lee, Bradley H. King, Andrew R. Morton, Ryan C. Gimple, Melike Pekmezci, Zhe Zhu, Jair L. Siqueira-Neto, Xiuxing Wang, Qi Xie, Clark Chen, Gene H. Barnett, Michael A. Vogelbaum, Stephen C. Mack, Lukas Chavez, Arie Perry, David R. Raleigh, Jeremy N. Rich

CANCER DISCOVERY (2020)

Article Infectious Diseases

Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole

Claudia Magalhaes Calvet, Tatiana Araujo Silva, Diane Thomas, Brian Suzuki, Ken Hirata, Jair Lage Siqueira-Neto, James H. McKerrow

PLOS NEGLECTED TROPICAL DISEASES (2020)

Article Infectious Diseases

Genome-scale metabolic models highlight stage-specific differences in essential metabolic pathways in Trypanosoma cruzi

Isabel S. Shiratsubaki, Xin Fang, Rodolpho O. O. Souza, Bernhard O. Palsson, Ariel M. Silber, Jair L. Siqueira-Neto

PLOS NEGLECTED TROPICAL DISEASES (2020)

Article Biochemistry & Molecular Biology

Human iPSC-Derived 2D and 3D Platforms for Rapidly Assessing Developmental, Functional, and Terminal Toxicities in Neural Cells

Ileana Slavin, Steven Dea, Priyanka Arunkumar, Neha Sodhi, Sandro Montefusco, Jair Siqueira-Neto, Janet Seelke, Mary Anne Lofstrom, Blake Anson, Fabian Zanella, Cassiano Carromeu

Summary: In response to the increasing global health threats, there is an urgent need to develop and deploy safe and effective therapies rapidly. Repurposing already approved therapeutics for new indications may lead to undesirable side effects due to changes in dosage, usage directives, and clinical context. Studies have shown that many compounds have high toxicity on early-stage neural tissues but not on later stages, emphasizing the importance of utilizing human neural cultures at different developmental stages to understand the neurotoxicity profile of potential therapeutics fully.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Microbiology

Dysregulation of Glycerophosphocholines in the Cutaneous Lesion Caused by Leishmania major in Experimental Murine Models

Adwaita R. Parab, Diane Thomas, Sharon Lostracco-Johnson, Jair L. Siqueira-Neto, James H. McKerrow, Pieter C. Dorrestein, Laura-Isobel McCall

Summary: Cutaneous leishmaniasis, caused by infection with a Leishmania parasite, affects 700,000 to 1.2 million new cases per year worldwide. Studying disease metabolism at the site of infection may lead to new targets for host-targeted drug development.

PATHOGENS (2021)

Article Infectious Diseases

Spatial metabolomics identifies localized chemical changes in heart tissue during chronic cardiac Chagas Disease

Danya A. Dean, Gautham Gautham, Jair L. Siqueira-Neto, James H. McKerrow, Pieter C. Dorrestein, Laura-Isobel Mccall

Summary: Chagas disease, caused by Trypanosoma cruzi, affects millions of people worldwide and can induce severe cardiac symptoms during the chronic stage. By analyzing the heart tissue metabolome of mice infected with T. cruzi, researchers identified specific metabolic changes in localized cardiac regions, highlighting the impact of parasite infection on host metabolism. Furthermore, discriminatory small molecules related to infection were identified, providing insight into the development of chronic cardiac symptoms in CD.

PLOS NEGLECTED TROPICAL DISEASES (2021)

Article Chemistry, Medicinal

Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L

Ittipat Meewan, Jacob Kattoula, Julius Y. Kattoula, Danielle Skinner, Pavla Fajtova, Miriam A. Giardini, Brendon Woodworth, James H. McKerrow, Jair Lage de Siqueira-Neto, Anthony J. O'Donoghue, Ruben Abagyan

Summary: Inhibitors containing thiuram disulfide or dithiobis-(thioformate) were found to be potential drugs against SARS-CoV-2. These compounds showed strong inhibitory effects in enzymatic and cell-based assays, suggesting their promise in the treatment of the COVID-19 virus or related variants.

PHARMACEUTICALS (2022)

Article Biochemistry & Molecular Biology

Antiviral activity of Cenostigma pluviosum var. peltophoroides extract and fractions against SARS-CoV-2

Jose Renato Pattaro-Junior, Ingrid Garcia Araujo, Carolina Borsoi Moraes, Cecilia Gomes Barbosa, Gisele Strieder Philippsen, Lucio Holanda Freitas-Junior, Ana Carolina Guidi, Joao Carlos Palazzo de Mello, Rosane Marina Peralta, Maria Aparecida Fernandez, Robson Ricardo Teixeira, Flavio Augusto Vicente Seixas

Summary: This study aimed to find potential compounds inhibiting SARS-CoV-2 from extracts of Brazilian plants. Experimental validation showed that ethyl acetate fraction and F2, F4 sub-fractions of C. pluviosum extract exhibited good antiviral activity in infected cells. These results may be attributed to the synergistic effect of different hydrolyzable tannins present in the extract.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2023)

Article Nanoscience & Nanotechnology

Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation

Monica Josiane Rodrigues-Jesus, Marianna Teixeira de Pinho Favaro, Alexia Adrianne Venceslau-Carvalho, Maria Fernanda de Castro-Amarante, Bianca da Silva Almeida, Mariangela de Oliveira Silva, Robert Andreata-Santos, Cecilia Gomes Barbosa, Samantha Carvalho Maia Brito, Lucio H. Freitas-Junior, Silvia Beatriz Boscardin, Luis Carlos de Souza Ferreira

Summary: This study reports a COVID-19 subunit vaccine based on nano-multilamellar vesicles (NMV) and monophosphoryl lipid A (MPLA) technology. The research shows that the vaccine can improve antibody and T-cell responses without toxic effects. Additionally, the vaccine formulation reduces the number of doses required to achieve enhanced serum virus-neutralizing antibody titers.

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2022)

Review Biotechnology & Applied Microbiology

Antimalarial drug discovery: progress and approaches

Jair L. Siqueira-Neto, Kathryn J. Wicht, Kelly Chibale, Jeremy N. Burrows, David A. Fidock, Elizabeth A. Winzeler

Summary: Recent efforts in antimalarial drug discovery aim to develop new drugs that can overcome emerging drug resistance, consider safety and improve dosing convenience. These efforts have led to the discovery of a variety of new molecules with novel modes of action, some of which are currently in late-stage clinical development. Prioritizing new drug candidates is crucial due to limited funding, and these candidates should demonstrate high potency, low resistance, infrequent dosing, low cost, safety and tolerability, and preferably the ability to block Plasmodium transmission. This review provides insights into successful approaches, progress in preclinical and clinical development, and challenges in antimalarial drug discovery.

NATURE REVIEWS DRUG DISCOVERY (2023)

Article Multidisciplinary Sciences

SARS-CoV-2 Spike protein peptides displayed in the Pyrococcus furiosus RAD system preserve epitopes antigenicity, immunogenicity, and virus-neutralizing activity of antibodies

Victor Bolsanelli Cioffi, Maria Fernanda de Castro-Amarante, Aleksei Lulla, Robert Andreata-Santos, Mario Costa Cruz, Ana Carolina Ramos Moreno, Mariangela de Oliveira Silva, Bianca de Miranda Peres, Lucio Holanda Gondim de Freitas Junior, Carolina Borsoi Moraes, Edison Luiz Durigon, Nicola Coker Gordon, Marko Hyvoenen, Luis Carlos de Souza Ferreira, Andrea Balan

Summary: This study utilized the RAD display system to present peptides derived from the SARS-CoV-2 Spike protein, leading to the detection of specific antibodies and the generation of inhibitory antibodies against viral infection. The RAD display system shows promise as a platform for peptide-based vaccine antigen design, epitope-specific antibody mapping, and the development of diagnostic and therapeutic antibodies.

SCIENTIFIC REPORTS (2023)

No Data Available